Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct;70(10):e30492.
doi: 10.1002/pbc.30492. Epub 2023 Jun 10.

Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in children

Nitya Gulati  1 , Lisa Giulino-Roth  1
Affiliations
Editorial

Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in children

Nitya Gulati et al. Pediatr Blood Cancer. 2023 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma.
    Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, Wohlgemuth WA, Mauz-Körholz C, Körholz D, Kluge R, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Attarbaschi A, Ceppi F, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Moellers M, Buerke B, Stoevesandt D. Franke FC, et al. Pediatr Blood Cancer. 2023 Aug;70(8):e30421. doi: 10.1002/pbc.30421. Epub 2023 May 27. Pediatr Blood Cancer. 2023. PMID: 37243889

References

REFERENCES

    1. SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries (excluding Illinois and Massachusetts). Surveillance Research Program, National Cancer Institute; 2023. Accessed May 31, 2023. https://seer.cancer.gov/statistics-network/explorer/
    1. Voorhees TJ, Beaven AW. Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma. Cancers (Basel). 2020;12(10):2887. 10.3390/cancers12102887
    1. NCCN guidelines for pediatric Hodgkin lymphoma V.2.2023. Accessed May 29, 2023. NCCN. www.nccn.org
    1. Chen CH, Hsiao CC, Chen YC, et al. Rebound thymic hyperplasia after chemotherapy in children with lymphoma. Pediatr Neonatol. 2017;58(2):151-157. 10.1016/j.pedneo.2016.02.007
    1. Fouda A, Kandil S, Hamid G, Boujettif K, Mahfouz M, Abdelaziz M. Rebound (reactive) thymic hyperplasia after chemotherapy in children with lymphoma. An Pediatr (Engl Ed). 2019;91(3):189-198. 10.1016/j.anpedi.2018.10.021

LinkOut - more resources